Skip to content

medcelerator · clinician one-pager

First FDA-Approved Treatment for Chronic Hepatitis D

Hepcludex (bulevirtide) for chronic hepatitis D (HDV)

Health Canada/FDA Approved · United States, Canada, European Union · September 7, 2026

Condition: Chronic Hepatitis D

Who this is for

Hepcludex (bulevirtide) is the first approved medicine for chronic hepatitis D. The United States gave accelerated approval to a daily 8.5 mg shot in May 2026. Canada and Europe approve a daily 2 mg dose.

Next clinical step

Health Canada and the US Food and Drug Administration (FDA) have approved this medicine. In Canada, the United States and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=hepatitis%20D&intr=bulevirtide&aggFilters=status:rec

General resources for further research

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/hepcludex-bulevirtide